GlassScriptPhysician profile
Tejpreet Singh Lamba
NPI 1861702623
$7,082.79
in general payments reported to CMS, 2019-2025
34 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $772 · 2021: $857 · 2022: $1,121 · 2023: $1,191 · 2024: $958 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Travel and Lodging: $323 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.77 |
| Travel and Lodging | $322.94 |
| Education | $300.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,481.61 | 2019-2024 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,306.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Noah Medical Corporation | $731.41 | 2024-2025 | Galaxy |
| Regeneron Healthcare Solutions, INC. | $572.56 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.16 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $337.70 | 2019-2025 | |
| Grifols USA, LLC | $306.92 | 2019-2023 | Prolastin-C Liquid |
| Ethicon INC. | $254.25 | 2021-2023 | Monarch Platform |
| Insmed, INC. | $191.44 | 2019-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $170.12 | 2019-2024 | |
| Philips North America LLC | $133.58 | 2019-2024 | (Ak6) Vest Therapy |
| Janssen Pharmaceuticals, INC | $126.91 | 2019-2022 | |
| Inspire Medical Systems, INC. | $95.38 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Merck Sharp & Dohme LLC | $94.16 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.05 | 2019-2023 | |
| Mindray Ds USA, INC. | $90.92 | 2023 | Te X, Te7 Max |
| Edwards Lifesciences Corporation | $89.54 | 2024 | |
| Resmed Corp | $83.44 | 2019-2025 | |
| Genentech USA, INC. | $39.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.89 | 2022 | |
| Amgen INC. | $35.87 | 2022-2024 | Tezspire |
| United Therapeutics Corporation | $33.64 | 2021-2023 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $31.05 | 2019 | |
| Mylan Specialty L.P. | $28.90 | 2019-2022 | |
| Lilly USA, LLC | $27.54 | 2025 | Zepbound |
| Vapotherm INC | $23.13 | 2019 | |
| Zimmer Biomet Holdings, INC. | $21.85 | 2019 | |
| Baxter Healthcare | $21.55 | 2023 | Hillrom - Monarch Airway Clearance System |
| Z-Medica, LLC | $19.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.67 | 2020 | |
| Shire North American Group INC | $17.39 | 2019 | |
| Avanos Medical | $16.44 | 2019 | |
| Monaghan Medical Corporation | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejpreet Lamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.